adebrelimab + nab-paclitaxel + carboplatin

This is a novel, experimental treatment regimen that combines an anti-PD-L1 antibody (adebrelimab) with two chemotherapy agents (nab-paclitaxel and carboplatin). **Components:** * **Adebrelimab:** A PD-L1 immune checkpoint inhibitor. * **Nab-paclitaxel:** An albumin-bound formulation of the microtubule inhibitor paclitaxel, designed to increase intratumoral drug concentration and potentially reduce certain toxicities compared to solvent-based paclitaxel. * **Carboplatin:** A platinum-based chemotherapy agent that causes DNA crosslinking. **Rationale:** The combination aims to leverage the complementary mechanisms of action: immune checkpoint inhibition by adebrelimab to enhance anti-tumor immunity and the cytotoxic effects of nab-paclitaxel and carboplatin to directly kill cancer cells.

Brand names

Abraxane

Other names

paclitaxel protein boundnab-paclitaxelalbumin-bound paclitaxel